NEWS
Taiwan, January 12, 2022 – Credo Diagnostics, a leader in the development of advanced MedTech diagnostics solutions, is proud to announce that we have successfully installed 6 VitaPCR™ Instruments on the cruise ship Explorer Dream (探索夢號). By providing a true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology, cruise tours were able to resume.
In a close-contact environment like the cruise ship, the transmission risk of SARS-CoV-2 from person to a person significantly increases with the movement of large numbers of people in such a closed setting. Therefore, in addition to social distance and regular sanitization measures, testing for COVID-19 is also an important way to protect everyone regardless of vaccination status. The VitaPCR™ SARS-CoV-2 Assay, based on the proprietary RT-PCR technology, enables COVID-19 detection in 20 minutes to provide timely diagnosis, helping healthcare personnel make accurate and immediate healthcare management decisions on board.
Our VitaPCR™ SARS-CoV-2 Gen 2 Assay is able to detect COVID19 in 20 minutes with the all-important Ct value. By providing quick and accurate testing, the safety of the staff and crew members and passengers was not compromised. Importantly, Credo Diagnostics solution helps open up the resumption of the luxury cruise industry.
Credo Diagnostics have successfully installed 6 VitaPCR™ Instruments on the cruise ship Explorer Dream (探索夢號)
Credo Diagnostics solution helps open up the resumption of the luxury cruise industry.
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Taiwan, January 10, 2022 –Credo Diagnostics Biomedical Pte. Ltd. is delighted to announce that both VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets have obtained the CE IVD mark. These control sets are intended to be used for quality control testing with a series of VitaPCR™ Assays (exclude VitaPCR™ SARS-CoV-2 Assay, Cat# PCRAE0114)
VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets consist of droppers and disposable positive controls. The positive control is noninfectious in-vitro transcribed RNA in a lyophilized state, which can be conveniently stored at room temperature. With the control sets, the user is able to conduct quality testing to affirm the assay performance anywhere and anytime without the risk of control degradation and contamination.
VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets are recommended to be used during each time a new shipment of kits is received or when training a new operator; or in accordance with local regulations, accrediting groups, or laboratory’s standard quality control procedures.
For more information, please contact: service@credodxbiomed.com
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Taiwan, January 7, 2022 –For all diagnostic procedures to test COVID-19, performing these tests at POC or near-POC requires a suitable and sufficient risk assessment and implementation of appropriate control measures. It is essential that the rapid testing procedure, which may involve swab stirring/mixing into an elution buffer with the potential for associated generation of aerosols, does not place individuals performing these tests at an increased risk of SARS-CoV-2 exposure. It is therefore highly desirable that rapid testing procedures include a step that reduces the titer of infectious virus presents, e.g., by eluting samples into an effective lysis buffer.
In a study to assess the inactivation effectiveness of sampling buffers used, the UK National Infection Service (NIS) laboratories recently published in the Nature Scientific Reports to demonstrated the VitaPCR™ sample collection buffer is able to inactivate SARS-CoV-2 effectively, which provides clinicians in the front line with sufficient protection against SARS-CoV-2.
According to the study results, a >5.0 log10 reduction in SARS-CoV-2 titer was confirmed after one-minute treatment with VitaPCR™ sample collection buffer, which went up to 6.2 log10 reduction after a five-minute mixing. Data presented in this study showed the capability of VitaPCR™ sample collection buffer to ensure the protection of test operators, which also meets the requirement of the British European standard BS EN 14476 for effectiveness against viruses.
VitaPCR™ sample collection buffer, the next-generation (guanidine-free) nucleic acid extraction buffer, not only inactivates SARS-CoV-2 during contact but also eliminates the chemical hazards associated with conventional guanidine-based reagents in diagnostic procedures.
For more information, please refer to https://rdcu.be/cEsqk or contact us at: service@credodxbiomed.com
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Taiwan, January 1, 2022 –It is with great pleasure that we announce the establishment of our Branch in the Republic of China, Taiwan. This important milestone comes as part of our continuous efforts to expand our reach and make our products and services as widely available as possible. Importantly, this initiative continues our focus, ADVANCED MEDTECH FOR ALL.
The choice of Taiwan is very clear.
“As a member of international organisations such as the World Trade Organisation (WTO) and the Asia Pacific Economic Cooperation (APEC), Taiwan is highly free in economic activities. Coupled with its economic stability and measures being taken to cut red tape and remove bureaucracy from business procedures, it was an easy decision”, said Dr. Winston Wong Jr., Chairman and CEO of Credo Diagnostics Biomedical.
“Besides, Taiwan has demonstrated that their diversified pool of biotech talents has high-quality standards. In addition to their outstanding medical system, Taiwan offers a comprehensive supply chain for the biomedical industry. Taking advantages of the many business friendly offerings in Taiwan, Credo Diagnostics aims to provide excellent and accurate medical solutions to improve the lives of people around the world.”
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Media Contact:
Cheryl Yang
Tel: +886 2-2697-3998 Ext.1116
Email: cheryl.yang@credodxbiomed.com
Singapore, December 22, 2021 – Credo Diagnostics is proud to be on the list of “Top 50 Healthcare Startups in Singapore” published by StartupLanes. We vow to accelerate the molecular test and provide it at an affordable cost. Being on the list of Top 50 Healthcare Startups is a great reward to our efforts and our pursuit to the mission “Advanced Medtech for All” will never stop.
Read more details：https://lnkd.in/gui6iSa2
About StartupLanes
StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.StartupLanes offers dedicated Investment Banking services for startups. No Retainer Fee, Only Activation, and Success Fee.
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Singapore, December 21, 2021 – In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on December 17th, 2021.
According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay is capable of correctly detecting the new Omicron strain, including B.1.1.529 BA.1 and BA.2.
Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly
Another four Variants of Concern (VOC):
． Alpha variant: known as B.1.1.7
． Beta variant: known as B.1.351
． Gamma variant: known as P.1
． Delta variant: known as B.1.617.2
Two Variants of Interest (VOI):
． Lambda variant: known as C.37
． Mu variant: known as B.1.621
The other six variants:
． Eta variant: known as B.1.525
． Iota variant: known as B.1.526
． Kappa variant: known as B.1.617.1
． Zeta variant: known as P.2
． Epsilon variant: known as B.1.427/B.1.429
． Indian variant: known as B.1.617.3
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.